S100A9 and myeloid sarcoma: S100A9 is also up-regulated in other diseases with a neuro-inflammatory component, including traumatic brain injury (TBI) [81], post-operative cognitive dysfunction (POCD) [82], and multiple sclerosis (MS) [83]; broadening the potential therapeutic applications of ORY-2001.